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Most attempts to prolong the survival of allografts have involved treatment of the host to 
impair its capacity to reject them. Early uncritical attempts to treat the graft rather than the 
host were received with skepticism because of the prevailing belief that the alloantigens on 
cell surfaces are immutable. However, over the past decade unequivocal evidence has 
accumulated that the immunogenicity of allografts is susceptible to alteration. 
Short-term maintenance in vitro of malignant and normal tissue grafts, such as those of the 
ovary and thyroid. weakens their susceptibility to rejection. Various agents have been 
identified which, when applied to tissues or organs in vitro, have a similar effect. Soaking 
skin in media containing steroids, urethane, thalidomide, antilymphocyte globulin (ALG), 
and specific alloantibody is also effective. X-irradiation and perfusion of allogeneic dog 
kidneys with solutions of concanavalin A or of nucleic acid prepared from the future donor or 
even from indifferent donors or microorganisms lead to extended survival. There is also 
equivocal evidence that soaking mouse skin grafts in RNA prepared from unrelated donors 
causes them to be treated as allogeneic by syngeneic recipients. 
Skin from animals suffering from certain diseases displays altered immunogenicity. Skin 
from mice suffering from virus-induced leukemia or lymphocytic choriomeningitis is 
frequently rejected by syngeneic recipients. By contrast, skin allografts from some cancer 
patients and from mice bearing certain tumors give evidence of prolonged survival as do 
grafts from uremic mice. Some treatments of prospective donors, including cytotoxic drugs, 
ALG, specific alloantisera, hypoxia, and experimentally produced uremia, also extend the 
lives of allografts. Trophoblast, a fetal epithelial tissue in immediate contact with maternal 
tissue, represents a natural example of graft adaptation. Despite its origin from precursor 
cells with normal transplantation properties, trophoblast fails to elicit transplantation 
immunity and is unaffected by it. 
Some of the disparate agents or procedures described here probably act by modifying grafts 
in such a way that they are more likely to evoke "blocking" or enhancing antibodies rather 
than the usual destructive cellular immunity, and many of them deplete the grafts of 
immunogenically effective "'passenger" leukocytes. Both of these processes contribute to 
apparent hypoantigenicity. 
Ever since the incompatibility of tissue and 
organ grafts exchanged between unrelated individ-
uals of the same species was shown to have an 
immunogenetic basis, most workers in the field of 
transplantation biology and in the allied field of 
blood transfusion have accepted the dogma that 
the antigenic structure of grafted allogeneic cells is 
unchanging and unchangeable. Indeed, to many 
this dogma still seems reasonable since 
histocompatibility or transplantation antigens are 
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integral, functionally important components of cell 
membranes and are widely distributed throughout 
the tissues of the body [1]. 
Consequently, nearly all systematic attempts to 
prolong the survival of allografts have involved 
treatment of the host to impair its capacity to react 
effectively against the alien antigens of the grafted 
cells. This approach has been highly successful at 
the laboratory level [2]. Unfortunately, the clini-
cally applicable procedures, though widely used in 
renal transplantation, are still far from ideal. 
Many problems of organ transplantation, could be 
minimized if early rejection episodes could be 
mitigated by modifying the graft after, or possibly 
even before, its removal from the donor. 
Empirical attempts to prolong the lives of allo-
grafts by altering their capacity to evoke a reaction 
or, even more optimistically, to enable them to 
override a state of sensitivity directed against 
them, have been made since the beginnings of 
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transplantation immunobiology. Despite a few ex-
aggerated claims most of this work was unsuccess-
ful. However, over the past decade evidence has 
accumulated that the immunogenicity of certain 
types of allograft is to some extent amenable to 
experimental manipulation. The purpose of this 
article is to survey and evaluate the current status 
of this facet of transplantation. 
MAINTENANCE OF GRAFTS IN VITRO BEFORE 
ALLOTRANSPLANTATIO N 
The belief that cuI turing or maintaining tissue in 
a medium containing plasma proteins from a 
prospective recipient might result in some modifi-
cation that would favor its survival after transplan-
tation has repeatedly been put to the test [3]. In 
1934, Stone, Owings, and Gey [4] reported the 
successful treatment of a patient with parathyroid 
tetany by means of parathyroid grafts prepared in 
this manner. Martinovitch [5] and Gaillard [6], 
independently, advocated that the prospective 
allograft be maintained in vitro under conditions 
that restrict proliferation and cell outgrowth, 
claiming considerable success with pituitary grafts 
in animals and with parathyroid grafts in patients 
suffering from parathyroid tetany after thyroidec-
tomy, respectively. Gaillard maintained human 
fetal parathyroids in vitro for 14 days before 
transplantation to the perivascular lymph spaces 
around the axillary artery or vein. Unfortunately, 
this claim was not substantiated by evidence that 
the graft survived after transplantation or that 
exposure of the grafts to host plasma proteins was 
important. The possibility of spontaneous recovery 
on the part of the patient was not excluded (see 
[7]) . 
Regardless of the validity of these claims, care-
fully controlled experimental studies on both ma-
lignant and normal tissue allografts have estab-
lished unequivocally that short-term maintenance 
in vitro can extend their life expectancy after 
allotransplantation. Jacobs and Huseby [8], Ja-
cobs [9], and Jacobs and Uphoff [10], who main-
tained various murine and rat tumors in organ 
culture in a minimal synthetic medium for as little 
as 6 days under conditions of little or no prolifera-
tive activity, showed that this treatment often 
prolonged their survival or enabled them to be 
transplanted serially in a high proportion of nor-
mally resistant, major-locus histoincompatible, 
allogeneic hosts. These "in vitro" modified tumors 
did not grow in all allogenic hosts, and hosts which 
rejected primary grafts of the modified tumor were 
usually refractory if rechallenged with a similar 
tumor. Analysis of this phenomenon has shown 
that: (1) the in vitro acquired alteration in trans-
plantability to normally resistant hosts is fully re-
versible, e.g., by a single passage through a syn-
geneic host; (2) grafts of the altered tumor are fully 
susceptible to previous or concomitant specific 
sensitization of allogeneic hosts by allografts of the 
unmodified tumor or by skin allografts from donors 
of its strain of origin; (3) sustenance of the altered 
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tumor by allogeneic hosts sometimes enables sub-
sequent allografts of the unaltered tumor to survive 
and such transplants behave thereafter just like 
the in vitro altered tumors; and finally (4) hypo-
reactivity to skin allografts is demonstrable in hosts 
that have sustained allografts of the altered tumor. 
These and other observations indicate that the 
ability of the modified tumor allografts to induce 
transplantation immunity is associated with a 
mechanism which appears to alter the phenotypic 
expression of histocompatibility genes. This, in 
turn , results in a specific hyporeactive state in the 
host which may be a consequence of the appear-
ance of enhancing or blocking antibodies [2,11] 
which frustrate the development or the expression 
of the usual cellular immunity. Selection of rela-
tively compatible cells from the tumor cell popula-
tion at risk is a very unlikely explanation. How-
ever, removal of "passenger" leukocytes from the 
tissues as a consequence of the treatment in vitro 
might contribute something to the reduced immu-
nogenicity of the tumor (see below). 
In 1973, Summerlin, et al [12] evoked wide-
spread interest in the feasibility of culture-induced 
adaptation of allografts in vitro, and even of 
heterografts, of various tissues, but notably of skin. 
They stated that, in mice and men, allografts of 
skin were accepted for long periods after having 
been maintained in vitro for 4 to 6 weeks (man) or 
as little as 7 to 10 days (mouse) . They claimed that 
donor-specific histocompatibility antigens were re-
tained in cells from such long-established skin 
allografts. There were, however, indications that 
the findings had been misrepresented [13] and 
other workers failed to reproduce the results [14]. 
However, after this widely publicized episode in 
the history of transplantation, well-controlled ex-
periments by other investigators [15,16] estab-
lished that as a result of maintenance in vitro for 3 
to 13 days a significant proportion of allografts of 
ovarian tissue from infant or adult donors were 
able to override major histoincompatibility bar-
riers in ovariectomized mice. 
Another tissue shown to be amenable to this 
"adaptive" treatment is thyroid. Lafferty et al [17] 
have reported that with the BALB/c-C57BL and 
other donor/host mouse strain combinations, hold-
ing thyroid allografts in organ culture for 12 days 
before transplanting them beneath the renal cap-
sules of thyroidectomized hosts at least doubled 
their survival. Some grafts maintained in vitro for 
4 weeks manifested no histologic signs of rejection 
as late as 40 days after transplantation. In this 
study, functional survival of the transplanted thy-
roid tissue was established on the basis of its 
ability to take up 1251. Grafts were also recovered 
and scored histologically for corroborative evidence 
of survival at the time. 
Evidence has been obtained that this principle 
also applies to lymphocytes. If human peripheral 
blood lymphocytes are cultured in vitro in the 
presence of HL-A complex-incompatible stimula-
tory allogeneic cells-most conveniently living 
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lymphocytes-they respond by DNA synthesis and 
blast cell transformation; this response is believed 
to represent the first recognitive event of the 
allograft response in vivo [1,2]. Opelz and Tera-
saki [18 J and others [19 J have found that when 
putative stimulatory lymphocytes are maintained 
in culture at 22°C, their ability to stimulate fresh 
"responder" lymphocytes declines after a week. 
Nevertheless, the same cells retain their ability to 
respond to allogeneic stimulator lymphocytes over 
a 10-day culture period. The simplest interpreta-
tion is that maintenance in vitro diminished the 
concentration or availability of stimulatory anti-
gens on the cell surface membranes. In contrast to 
the effect that short-term maintenance of lympho-
cytes has on their stimulatory ability, lymphoblast 
lines maintained in long-term culture retain their 
ability to act as stimulator cells. 
TREATMENT OF GRAFTS IN VITRO BEFORE 
TRAN SPLANTATIO N 
Nucleic Acids 
Unequivocal evidence that extracellular DNA or 
RNA is incorporated into bacterial and mamma-
lian cells and that the incorporated nucleic acids 
bring about the cells' transformation has prompted 
several workers to apply this principle to alter the 
immunogenicity of skin and kidney grafts. In 1964, 
Guttmann, Kraus, and Dolan [20] reported that 4 
hours' exposure in vitro of freshly excised grafts of 
mouse skin to a solution of RNA prepared from 
livers of mice of an allogeneic strain caused a high 
proportion of the grafts to be rejected within 10 to 
27 days after transplantation to syngeneic hosts. 
Grafts incubated with " syngeneic " RNA before 
being transplanted to syngeneic hosts behaved just 
like autografts, and this finding eliminated the 
possibility that nonspecific toxicity of the RNA 
preparations was responsible for the demise of the 
syngeneic grafts treated with alien RNA. These 
observations were confirmed and extended by 
Burrows, Muir, and Mowbray [21], who used 
highly purified, protein-free RNA prepared from 
liver and spleen to which they exposed their grafts 
for 1 hr in vitro at room temperature. These 
investigators reported that the ability of allogeneic 
RNA to confer immunogenicity upon syngeneic 
skin grafts was abolished by treatment with ribo-
nuclease but not with deoxyribonuclease . In both 
of these studies , histologic examination of grafts 
undergoing rejection revealed cellular events 
closely resembling those usually associated with 
the rejection of untreated allografts. 
However, Askonas and her colleagues [22] failed 
to reproduce the findings of Guttmann et al [20] 
using the same strains of mice but a different 
grafting technique. Of possible significance is the 
fact that despite the considerable expertise of this 
group in skin grafting in mice, they encountered a 
high proportion of technical failures , i.e., grafts 
which on primary inspection were unattached to 
their beds . This suggested that under the prevail-
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ing experimental conditions, incubation with RNA 
preparations was in some way toxic. Later Lem-
perle [23] claimed that previous incubation of 
murine skin allografts with high concentrations of 
DNA or RNA prepared from the spleens or skin of 
mice of a prospective allogeneic host strain signifi-
cantly prolonged their survival across both major 
locus and nonmajor locus histoincompatibility bar-
riers. In experiments in which syngeneic grafts 
were incubated with allogeneic DNA or RNA, he 
also confirmed the findings of Guttmann et al [20] 
and of Burrows and his associates [21 J. 
Lacking evidence that a donor-specific crop of 
fur was regenerated or that some other unambigu-
ous genetic "marker" was retained in a skin 
allograft which allegedly survived for a prolonged 
period after a particular treatment in vitro, we may 
reasonably ask whether the alien donor cell popu-
lation of the graft had not, in fact, undergone 
surreptitious replacement by native or host cells. 
The prolonged survival of treated renal allografts 
in bilaterally 'nephrectomized allogeneic hosts can 
be appraised much more objectively by measura-
ble functional criteria such as creatinine clearance 
or BUN levels or by their ability to sustain life. 
Groth et al [24] have reported that after blood 
was removed from canine renal and hepatic allo-
grafts by perfusion, exposure to a solution of RNA 
prepared from the spleens of prospective recipients 
or even indifferent dogs by perfusion for 35 to 65 
min, prolonged the function of about a fourth of 
the grafts. Maximum survival for the recipients of 
kidneys and livers was 123 and 46 days , respec-
tively. The effect of the RNA pretreatment was not 
improved by adding DEAE-dextran, a supposed 
RNase inhibitor, to the RNA perfusate; it was 
totally abolished, however, by the addition of 
RNas'e. Treatment of renal allografts with al-
logeneic RNA did not cause them to be rejected as 
allografts. 
These findings have been confirmed by Lem-
perle, Michaelis , and Mihatsch [25], who observed 
that canine renal allograft survival was signifi-
cantly prolonged after perfusion with RNA, DNA, 
or with mixtures of these nucleic acid solutions 
extracted from the spleen or a kidney of the 
prospective recipient. No such prolongation waE: 
observed in allografts perfused with similar nucleic 
acid solutions previously incubated with RNase 
and DNase, an indication that a contaminating 
protein was not responsible for the observed effect. 
The ability of RNA-containing perfusates to pro-
long the survival of renal allografts has also been 
reported by at least two other groups of investiga-
tors, who used nonspecific RNA prepared from 
yeast and Escherichia coli. The mechanism re-
sponsible still awaits elucidation. 
Corticosteroids 
In clinical organ transplantation, systemically 
administered corticosteroids are important as an-
cillary immunosuppressant agents. More than 20 
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years ago, topical application every 3 days of 
cortisone acetate or of 9a-f1uorocortisol acetate 
approximately doubled the life expectancy of skin 
allografts in rabbits, provided that in hosts bearing 
several grafts each graft was treated [7,26]. This 
principle has been extended to other corticosteroid 
hormones and, so far as rabbits are concerned , 
triamcinolone acetonide has proved to be the most 
effective agent. Klaue, Jolley, and Hinshaw [27] 
reported that incubating rabbit skin grafts for 60 
min at room temperature in a suspension contain-
ing 40 mg per ml of triamcinolone acetonide 
increased their survival by a factor of 3 after 
allotransplantation to normal hosts and to a lesser 
though still significant extent after transplantation 
to specifically presensitized hosts . Triamcinolone 
acetonide was not as effective in this species as in 
rabbits. However, at the concentrations used , 
these locally applied steroids exert a significant 
toxic effect on both the graft and its bed, impairing 
fibroblastic and epithelial cell activity. Like mono-
nuclear cell infiltration, healing in and revasculari-
zation of the treated grafts are delayed and epider-
mal regeneration is strikingly impaired during the 
rejection process. 
In the mouse, pretreatment of skin allografts in 
fluocinolone acetonide solution at a concentration 
of 10 mg per ml at 37 D C for 10 min is highly 
effective in prolonging survival [28]. Local applica-
tion of the drug to the graft bed before transplanta-
tion was less effective . Particularly encouraging 
from the viewpoint of clinical application is evi-
dence that fluocinolone acetonide in aqueous solu-
tion at a concentration of only 20 J.Lg per ml 
afforded a highly effective incubation medium 
which was without demonstrable deleterious ef-
fects on graft viability in mice. 
Experimental analyses indicate that these topi-
cally active steroid agents have only a trivial effect 
through local absorption and systemic action [29]. 
Their main impact seems to be exerted locally, 
where they impair the development of host sensiti-
zation (by interfering with the afferent arc of the 
immunologic response) and to perhaps a greater 
extent interfere with effecting the host response 
once it has been elicited (efferent inhibition). 
Urethane 
Some investigators have attempted to exploit 
evidence that treatment of tumor cells with certain 
chemical agents in vitro, particularly urethane, a 
relatively nontoxic nucleic acid antagonist and 
mitotic inhibitor, causes them to lose membrane 
antigens. Bonmassar et al [30] reported that incu-
bating rat skin allografts in vitro for 24 hr at 37 DC 
in a 2% buffered solution of urethane prolonged 
their survival for a few days. This treatment did 
not harm autografts. Cole and Davis [31] found 
that combining systemic treatment with urethane 
and whole-body x-irradiation impairs or inhibits 
allograft reactivity in both mice and dogs to a 
much greater extent than x-irradiation alone. 
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Thalidom ide 
In mice, thalidomide at nontoxic doses acts as a 
weak immunosuppressant so far as skin allografts 
are concerned. Furthermore, treatment of skin 
grafts with this drug in vitro somewhat prolongs 
their life expectancy on untreated allogeneic hosts 
[32]. 
Glutaraldehyde 
Even the recent literature on transplantation 
includes claims that strain one's credulity. In 1971, 
a report in the Proceedings of the National Acad-
emy of Sciences [33] stated that treatment of 
allografts of mouse skin in vitro with an approxi-
mately 0.3% solution of glutaraldehyde in phos-
phate-buffered saline for 20 min at room tempera-
ture , followed by washing, "prolonged their aver-
age survival time from 12.4 to 39.2 days. " It was 
suggested that covalent binding of the agent to the 
histocompatibility antigen sites (or in their close 
vicinity) shielded them from the recipient's im-
mune apparatus. One 's suspicions about the via-
bility of these long-lived grafts were aroused by 
the lack of histologic studies and the absence of 
information concerning hair regeneration , but 
most forcibly by the statement that glutaraldehyde 
treatment of syngeneic skin grafts resulted in their 
eventual rejection . 1m and Simmons [34] showed 
that grafts whose "survival" was prolonged by 
glutaraldehyde had, in fact, been rendered nonvia-
ble. The treated grafts became united to their beds 
and apparently remained supple and macroscopi-
cally normal for several weeks. Grafts treated in 
vitro with formaldehyde or cyanide or subjected to 
freeze-drying behave somewhat similarly. Such 
grafts may have some application as temporary 
nonviable wound " dressings." 
Antilymphocy te Globulin 
In experimental animals, antilymphocyte globu-
lin (ALG) administered systemically is a powerful 
and relatively innocuous immunosuppressant. It is 
relatively specific for lymphocytes but is absorbed 
by cells of other types. In 1969, Raju, Grogan, and 
Hardy [35] reported that soaking freshly excised 
rat skin grafts in rabbit antirat-lymphoid cell 
antiserum for 3 hr at 4 DC significantly prolonged 
their survival after allotransplantation. The inci-
dence of functionally successful penetrating cor-
neal allografts was improved in normal rabbits 
after pretreatment of the grafts in vitro with ALG . 
According to Chandler et al [36], soaking the grafts 
in succinolated heterologous antirabbit lympho-
cyte antibody raised in guinea pigs provides better 
protection than that afforded by the ALG. Other 
investigators have reported that in rabbits, pre-
treating prospective penetrating corneal allografts 
in vitro with ALG affords them some degree of 
protection against active immunization of their 
hosts after they have healed in [37]. 
Callender et al [38], recognizing that no treat-
ment of normal tissue or organ allograft is likely to 
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result in a complete or long-lasting abrogration of 
its immunogenicity, evaluated the survival of ca-
nine renal allografts perfused with goat antidog 
lymphocyte serum in vitro before transplantation 
to minimally immunosuppressed, bilaterally ne-
phrectomized hosts treated with azothioprine 2.5 
mg per kg per day. This drug regimen failed to 
prolong the survival of renal allografts perfused 
either with Ringer's lactate solution or dog plasma, 
but it did extend the mean survival time of the 
ALG-perfused renal grafts from about 15 days to 65 
days. The modus operandi of the apparent reduc-
tion in immunogenicity needs to be elucidated; 
opsonization of "passenger leukocytes" and the 
masking of transplantation antigens on cell sur-
faces by nonspecifically bound goat immunoglobu-
lin are two obvious possibilities. 
Concanavalin A 
Again using minimally immunosuppressed dogs 
to demonstrate reduction of immunogenicity pro-
duced by in vitro manipulation, Simmons et al [39] 
studied the effect of perfusing renal allografts with 
concanavalin A (Con-A) on their life expectancy. 
Factors governing the selection of this substance 
for study were its known ability to bind to murine 
lymphoid cells and to prevent their complement-
dependent lysis by specific H-2 isoantibody. Perfu-
sion of the kidneys with Con-A at an optimum 
concentration of 25 mg per liter in Ringer's lactate 
solution at 4°C prolonged their survival in mini-
mally immunosuppressed hosts. However, if after 
perfusion with the Con-A the organs were perfused 
with large volumes of Ringer 's lactate solution or 
with a small volume of plasma, their survival was 
not extended. Furthermore, initial perfusion with 
Con-A at room temperature was ineffective. These 
and other findings indicate that the Con-A binds 
only loosely to the renal tissue , pr'esumably to the 
vascular endothelium. However, that its effect is 
exerted locally was indicated by the ineffectiveness 
of Con-A administered into the renal artery of the 
graft after transplantation. Recent findings that 
Con-A can activate so-called suppressor T -lym-
phocytes which can exert a restraining influence 
upon cell-mediated immune responses as well as 
upon antibody synthesis suggest the explanation of 
these interesting findings [40]. 
Irradiation 
Steinmuller et al [41] have demonstrated in the 
rat that the functional survival times of both renal 
and auxiliary cardiae allografts can be prolonged 
by isolating and chilling the organs in ice-cold 
saline and then exposing them to high doses of 
x-irradiation before transplantation. They sug-
gested that this treatment reduces the immunoge-
nicity of the grafts by decreasing their passenger 
leukocyte content rather than by destroying or 
denaturing the transplantation antigens associated 
with the graft parenchyma or vascular endothe-
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lium. Attempts to extend this principle to renal 
allografts in dogs have so far been unsuccessful 
[42]. 
APPARENT ADAPTATIO N OF THYROID ALLOGRAFTS 
THRO UGH RESIDENCE IN THE ANTERIOR 
CHAMBER 
In acorn parative study on thyroid tissue allo-
grafts implanted subcutaneously or into the ante-
rior chambers of the eyes of outbred, thyroidecto-
mized guinea pigs, the Woodruffs (see [7]) found 
that whereas the majority of the intraocular grafts 
became vascularized and survived indefinitely, the 
subcutaneous grafts usually underwent rapid rejec-
tion. Furthermore, the intraocular grafts gradually 
lost their initial susceptibility to later specific 
sensitization of their hosts by subcutaneous trans-
plantation of a second thyroid allograft from the 
original donor. In a high proportion of cases in 
which long-established intraocular allografts were 
recovered and transferred to a subcutaneous site in 
the same host, they became vascularized and 
survived indefinitely. This observation indicated 
that some kind of adaptation must have taken 
place either in the graft or in the host; the 
Woodruffs favored the former possibility. 
Our own attempts to demonstrate in hamsters or 
guinea pigs that skin allografts sustained in im-
munologically privileged sites either weaken the 
host's capacity to respond to the alloantigens 
concerned or undergo some kind of immunogenic 
enfeeblement, possibly through loss of passenger 
cells, have been unsuccessful [43]. Warden, 
Reemtsma, and Stein muller [44] have confirmed 
and extended the Woodruffs' observations in stud-
ies on inbred strains of rats. They transplanted 
DA-strain thyroid tissue allografts to the anterior 
cham bers of thyroidectomized Fischer-strain 
hosts . After 3 months, the grafts were recovered 
and transplanted subcutaneously either in the 
same animal or into a normal rat of the same 
strain. Only the first category of graft survived, an 
indication that adaptation must have taken place 
at the level of the host rather than of the graft. 
Their suggestion that active immunologic en-
hancement of the host was responsible for weaken-
ing its reactivity has received support from recent 
findings of Streilein et al [45] that intraocular 
exposure of rats to allogeneic lymphoid cells elicits 
a vigorous humoral antibody response and weakens 
their capacity to reject skin grafts from the donor 
strain. 
The persistence of primary allografts in conven-
tional sites in initially immunosuppressed hosts 
which subsequently reject second grafts from the 
original or a genetically similar alien donor has 
been observed repeatedly. The factors that may 
contribute to this anomalous state of affairs, which 
is ascribed to graft adaptation, are the replacement 
of donor vascular endothelial cells as well as of 
passenger cells by cells from the host's blood 
stream. 
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TROPHOBLAST-NATURE'S SUCCESS IN ALLOGRAFT 
ADAPTATION 
One of the most enigmatic phenomena in trans-
plantation immunobiology is the successful devel-
opment to term of the mammalian fetus which is in 
effect engrafted in the maternal uterus. Despite its 
complement of paternally inherited transplanta-
tion antigens against which the mother is capable 
of reacting immunologically, the fetus, unlike 
nearly all other kinds of allografts, is exempt from 
rejection . Many lines of evidence point to the 
trophoblast, an epithelial tissue of fetal origin 
which forms the anatomic frontier in the fetal-ma-
ternal relationship, as fulfilling an immunologic 
quarantining role. It behaves as if it is neither 
capable of eliciting transplantation immunity nor 
susceptible to it. 
The immunologically unique properties of the 
trophoblast appear to stem from (1) the failure of 
trophoblast cells to express transplantation anti-
gens on their surfaces in an imm unologically signif-
icant form, probably as a consequence of the 
masking of these specificities by a relatively thick 
glycocalyx or cell surface coating or its equivalent, 
and (2) the possible local immunosuppressive ef-
fect of certain hormones secreted by the tropho-
blast which may prevent immunologic interaction 
between putative target trophoblast cells and ma-
ternal lymphocytes. 
The presence of transplantation antigens on the 
cells of pretrophoblastic embryos is well estab-
lished, and there is solid evidence that the tropho-
blast represents a highly specialized type of embry-
onic tissue that is incapable either of producing or 
at least of expressing on its surface isoantigens 
expressed by its immediate precursors; that is, it 
represents an important natural example of graft 
adaptation [46]. Some investigators have consid-
ered whether grafts could be treated in such a way 
as to cause their vascular endothelial cells to 
assume certain qualities normally associated with 
trophoblast cells, but how to approach this goal in 
a systematic manner is enigmatic. 
" ADAPTATIO N" OF BO NE MARROW AND LYMPHOID 
TISSUE GRAFTS-A SPECIAL CASE 
In man, transplantation of bone marrow or 
lymphoid tissue in the form of "cellular" grafts 
offers a rational therapy for various congenital 
diseases, as well as for diseases caused by drugs, 
chemicals, and irradiation. However, with all allo-
grafts of the lymphomyeloid complex we have to 
contend not only with the familiar host-versus-
graft (HVG) or allograft reactivity but also with 
the possible reactivity of T -lymphocytes of donor 
origin in the grafts against alien transplantation 
antigens of the host which would lead to GVH 
disease . 
Although both animal experiments and clinical 
trials have shown that the risk of GVH disease can 
frequently be reduced by careful donor selection or 
matching procedures, it still is a very serious 
clinical problem [47,48]. Many investigators have 
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tried to devise treatments of bone marrow or 
lymphoid cells in vitro which will deprive them of 
their capacity to generate clinically significant 
GVH reactions, while still retaining their benefi-
cial qualities. The methods explored include: irra-
diation in vitro, separation of the putatively harm-
ful cells by density gradient centrifugation, and 
incubation of the cells in vitro under conditions 
differentially inimical to T-Iymphocytes, e.g., with 
ALG, isoantibody, syngeneic liver cells, or thymic 
extract. Removal or inactivation of these poten-
tially harmful T -lymphocytes clearly represents a 
special kind of graft adaptation. 
DISEASES OF DO NORS WHICH LEAD TO ALTERED 
IMM UNOGENICITY OF THEIR TISS UES 
Virus -Associated Alteration in Antigenicity of 
Sy ngeneic Grafts 
Tumors induced by oncogenic viruses express a 
newly acquired antigen(s) capable of eliciting 
transplantation immunity in normal, syngeneic 
hosts . In general, all tumors induced by one 
particular virus seem to share at least one antigen 
in common so that antigenic specificity is deter-
mined by the virus rather than by the individual 
tumor. 
In 1964, Breyere and Williams [49] made the 
important observation that the cellular, tumor-
specific antigens associated with oncogenic viruses 
are not limited in their distribution to the tumors 
they induce but are also expressed by normal 
tissues of virus-infected hosts. They found that a 
significant proportion of skin grafts from BALB/c 
mice, which were leukemic as a consequence of 
neonatal inoculation with a leukemia virus, under-
went partial or complete rejection when trans-
planted to normal syngeneic hosts. Preimmuniza-
tion of the normal hosts with low dosages of the 
leukemic cells increased the proportion of skin 
grafts that were totally destroyed. The average 
time for rejection of the skin grafts by immune 
hosts was 18 days. 
These observations have been confirmed and 
extended to other tumor viruses acquired by the 
graft donors by vertical transmission as well as by 
infection in adult life [50,51]. Furthermore, other 
normal tissues besides skin acquire the new anti-
gen, and skin grafts from mice bearing various 
solid tumors are frequently rejected by normal 
syngeneic hosts, possibly as a result of infection 
with a virus which induces a new antigen. This 
phenomenon has been designated "heterogeniza-
tion" by Svet-Moldavsky and his associates [52]. 
A similar phenomenon appears to occur with 
certain other infections involving nononcogeneic 
viruses. For example, Holterman and Majde [53] 
have shown that skin grafts from mice chronically 
infected with lymphocytic choriomeningitis (LeM) 
virus are consistently rejected by syngeneic hosts 
within 12 to 14 days. These authors suggested that 
the virus-infected cells exhibit new antigenic de-
terminants on their surface membranes. 
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Apparent Hypoantigenicity of Allografts from 
Tumor-Bearing Donors 
Unlike the evidence just summarized of the 
acquisition of neoantigenicity by normal tissues of 
mice infected with oncogenic and other viruses is 
that of diminished immunogenicity (and increased 
resistance to allograft reactivity) of skin grafts 
from some cancer patients or tumor-bearing mice 
[54]. Attempts to elucidate the mechanism of this 
prolongation of survival of allografts from tumor-
bearing donors have been made and include anoxia 
associated with anemia and increased secretion of 
corticosteroid hormones. 
Udassin, Schlesinger, and Ben-Hur [55] inge-
niously set out to determine whether previous 
exposure of the donors to viable tumor cells is 
essential to obtain altered survival of allografts 
taken from them. They treated normal mice with 
frozen-stored, cell-free ascites fluid from random-
bred Swiss mice bearing Ehrlich ascites tumors. 
As a consequence of 6 consecutive daily injections 
of normal C3H mice with 0.1 ml of the fluid, the 
median survival time of skin allografts transplanted 
from them to normal A-strain hosts was prolonged 
from 10.7 ± 0.5 days to 13.2 ± 0.4 days. The sur-
vival expectancy of Y -antigen, incompatible skin 
isografts from similarly treated C57BL male mice 
on syngeneic females was also strikingly prolonged. 
Preliminary fractionation studies on the cell-free 
ascites fluid suggested that the active agent is an 
immunoglobulin, though they did not rule out the 
possibility of contamination by a virus capable of 
interfering with the host's immunologic response 
machinery. 
Prolonged Survival of Allografts from Uremic Mice 
Uremia in animals and man is often accompa-
nied by depressed immunologic reactivity evi-
denced in part by observations that skin allografts 
transplanted to uremic subjects may enjoy pro-
longed survival. Nirmal, Severin, and Taub [56] 
have recently completed a study on mice to deter-
mine the extent to which this weakened allograft 
reactivity associated with uremia results from 
alterations in the graft rather than in the host 's 
immune system. They found that skin allografts 
from donors made acutely uremic by bilateral 
ureteric ligation outlived grafts from normal, H-2 
locus compatible donors for a few days. Soaking 
skin allografts from normal donors with serum or 
serum globulin in vitro both from uremic and from 
'Jremic, bilaterally adrenalectomized mice also 
Drolonged their survival. 
The identity of the uremic serum globulin factor 
responsible for this phenomenon has yet to be 
determined. Probably the factor does not block 
:'elevant antigenic sites on the graft cells and 
decrease their immunogenicity because the ability 
;)f splenic cells from uremic mice to elicit trans-
')lantation immunity was unimpaired. A nonspe-
'ific, non adrenal steroid agent in the euglobulin 
raction of uremic serum may be involved. 
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REDUCTION OF IMMUNOGENICITY OF ORGAN 
ALLOGRAFTS BY PRETREATMENT OF THE 
DONOR 
Elimination of Passenger Leukocytes 
In certain types of allograft, a nonparenchymal 
population of drug-sensitive and x-ray-sensitive 
"passenger leukocytes" derived from bone marrow 
contributes to the overall immunogenicity [57,58J. 
This demonstration has stimulated attempts to 
improve the outcome of organ allotransplantation 
by treating the donor with cytotoxic drugs before 
harvesting. Sophisticated experiments with renal 
grafts and skin grafts in rats have established that 
whereas allogeneic passenger cells per se afford a 
sufficient immunogenic stimulus for rejection , they 
are certainly not the only allogeneic stimulus to 
elicit rejection . 
Pretreatment of donor rats with agents that 
cause leukopenia-e.g., whole body x-irradiation, 
cyclophosphamide, and ALG-can increase 
slightly the survival times of both renal and 
cardiac allografts and only very slightly of skin 
allografts especially when compatibility at the 
major histocompatibility complex prevails [59,60J. 
Dr. R. D. Guttmann, one of the pioneers of this 
approach, has reported improvement of renal allo-
graft function and reduction in rejection crises in 
patients receiving cadaver renal allografts from 
cadavers treated with multiple drug combinations 
for 5 hr [61] . Zincke and Woods [62] have shown 
that pretreatment of donor dogs with procarbazine 
hydrochloride and cyclophosphamide and other 
drugs for several hours before removal of their 
kidneys and transplantation to nonimmunosup-
pressed, bilaterally nephrectomized hosts pro-
longed their survival by a factor of more than two. 
They believe the delay in host reactivity may be due 
to a reduction or alteration in the immunogenicity 
of the passenger cell population, to some kind of 
alteration of the immunogenicity of the renal 
parenchymal cells, and to the activity of im-
munosuppressive agents incorporated in the renal 
allografts. 
Hypoxia-Induced Hypoantigenicity of Skin Grafts 
Furguson and Anthony [63 J have reported that 
14 days ' exposure of mice to a simulated altitude 
of 18,000 feet attenuated their ability to reject skin 
allografts. Furthermore, skin grafts removed from 
such animals enjoyed a slight but significantly 
longer life expectancy on normal allogeneic hosts 
than similar grafts from normal donors. These 
findings were tentatively ascribed to the depletion 
of lymphoid elements caused by the stress associ-
ated with exposure to reduced barometric pressure. 
Donor Enhancement 
A much-studied, but still incompletely under-
stood means of immunosuppression in transplan-
tation immunology is immunologic enhancement-
the specific frustration of the development or de-
ployment of the cell-mediated component of trans-
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plantation immunity by an isoantibody directed 
against alloantigenic specificities of cell surfaces 
[2]. The appropriate isoantibodies can be acquired 
either by active immunization of the host or by 
passive immunization. 
Barkin, Hambly, and Dimitriu [64] have found 
that daily treatment of C57BL/6 mice over a 5-day 
period with a high-titer antiserum, raised by active 
immunization of CBA mice with allografts of C57 
skin, prolonged the survival of their skin grafts by 
about 7 days when these were transplanted to 
normal, untreated CBA hosts. This "donor en-
hancement" was highly specific and still demon-
strable even in an extant state of sensitization 
initiated by a concomitant skin allograft from an 
untreated C57 donor. The latter graft was normally 
rejected, an indication that the systemic action of 
the enhancing antibody released from the treated 
allografts was not responsible for the phenomenon. 
This finding concurs with previous observations 
that perfusing skin (rabbits) or soaking it in vitro 
(rats) with specific antiserum before allotransplan-
tation prolongs survival. Critical experiments ex-
cluded systemic activity by the transferred anti-
body and suggested that it acted locally as a 
consequence of fixation to specific target antigens 
in the graft [65,66]. 
Treatment of Donors with Neuraminidase 
Neuraminidase is an enzyme which attacks the 
linkage between the terminal group of the oligosac-
charide N-acetylneuraminic acid and the deeper 
components of the cell surface, a variety of glyco-
proteins . It removes sialic acid from cells with a 
resultant decrease in their net negative cell surface 
charge; exposure of spleen and other cells to this 
enzyme in vitro increases their alloimmunogenici-
ty. Neuraminidase treatment of lymphocytes in 
vitro alters their subsequent behavior in syngeneic 
hosts in vivo. Madoff, McKenna, and Monaco [67] 
have shown that injecting mice with highly puri-
fied Vibrio cholerae neuraminidase (VCN) consid-
erably though transiently reduces (from 50-90%) 
the sialic acid content of various tissues, including 
lymph nodes, thymus, and spleen. Treatment of 
mice with this enzyme over an 18-day period 
significantly impaired their ability to reject skin 
allografts. The rejection of skin allografts from 
VCN-treated donors was accelerated in normal 
hosts. 
THE INFLUENCE OF MATERNAL ENVIRONMENT ON 
TISSUE IMMUNOGENICITY AND IMMUNOLOGIC 
RESPONSIVENESS 
Pregnancy is a very special kind of host-graft 
relationship and, as mammalian geneticists have 
long recognized, it affords an opportunity for the 
mother to influence her progeny in a manner that 
is denied the father. Indeed, the technique of ovum 
transplantation was originally developed to study 
maternal intrauterine influences on the conceptus. 
In an early study, Cloudman [68] found that 
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tumors of the foster mother's genetic make-up grew 
progressively in recipients of the ova-transfer sub-
strain and even in their descendants, but not in 
hosts of their strain of origin. 
Important studies on mice by Uphoff [10,69,70] 
over the past decade have shown that the maternal 
environment, including milk, can affect the pheno-
typic expression of both immunogenicity and im-
m unologic responsiveness in the progeny and that 
these phenotypic alterations are permanent and 
vertically transmitted from mother to offspring for 
many generations. To detect and study these 
changes, Uphoff has used three different kinds of 
experimental subjects: reciprocal hybrid mice, 
ova-transfer substrains, and foster-nursed sub-
strains. 
Reciprocal hybrid mice were produced by mat-
ing parents of two different inbred strains, so that 
females of each strain were mated to males of the 
opposite strain and produced, for example, both 
(A2 X Bo)Fl hybrids and (B2X Ao)Fl hybrid indi-
vid uals. Al though both of these classes of "reci pro-
cal" hybrids have identical genetic constitutions, 
they differ with regard to the maternal milieu in 
which they were gestated. Adult mice belonging to 
both classes of hybrids and produced by mating 
homozygous parents from two different strains 
were lethally irradiated and rehabilitated by 
infusion of bone marrow "grafts" from a donor of 
one or the other of the two parental strains. The 
delayed mortality caused by GVH reactivity was 
then evaluated. The severity of these reactions was 
significantly reduced when the marrow cell donors 
were syngeneic with the female parent which had 
gestated the hybrids under study. For example, 
when RIll strain bone marrow was injected into 
lethally irradiated (C57BL X RIIl)F 1 hybrids, the 
cumulative mortality was 50%; but when the 
genetically identical, reciprocal (RIll x C57BL)F 1 
hybrids were similarly treated, the cumulative 
mortality was only 20%. 
Not all parental strains, or rather their marrow 
celis, could "recognize" this apparently subtle 
quantitative reduction of antigenicity in the one 
class of F 1 hybrid host. However, an appropriate 
exposure in vitro to washed erythrocytes from one 
or other of the reciprocal hybrids before injection 
into the lethally irradiated subjects enabled them 
to do so. 
These findings have recently been confirmed by 
Morse, Harrison, and Asofsky [71] who transferred 
spleen cells from adult donors to sublethally irra-
diated infant reciprocal hybrids. 
Ova-transfer substrains were established by 
transferring homozygous fertilized eggs from a 
female of one genotype to the uterus of an appro-
priate female of a different genotype. Subse-
quently, an "adapted" male and an "adapted" 
female, born of the same foster mother, were made 
the progenitors of an ova-transfer substrain. 
Foster-nursed substrains were established by 
Caesarean delivery of term fetuses and foster nurs-
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ing them on homozygous allogeneic females; the 
same pattern of inbreeding as above was followed. 
Experimental studies on these substrains, which 
mostly entailed evaluating the ability of bone 
marrow grafts from them to elicit GVH disease in 
genetically appropriate, irradiated test hosts, have 
demonstrated a significantly diminished ability to 
respond to certain tissue antigens of the foster 
mothers' strain. Moreover, foster nursing and ova 
transfer altered the antigenicity of the host's tis-
sues from those of the original ancestral strain. 
Although too subtle to be detectable by skin 
grafting tests, they could be revealed with the aid 
of bone marrow grafts along the line indicated. 
Uphoff suggested that maternal modification in 
utero of the expression of the paternal 
histocompatibility phenotype, which results in 
diminished antigenicity, may be responsible for 
this phenomenon. Other possibilities have been 
considered by Morse et al [71]. 
CONCLUSION 
The various findings reviewed here (see also [72)) 
constitute a cogent argument that the apparent 
effective overall immunogenicity of allografts of 
both tissues and organs can be reduced by several 
more or less empirical procedures, most of which 
probably involve the destruction or removal of 
passenger leukocytes. In most situations, however, 
the latter does not afford a sufficient explanation 
for the prolongation of graft survival observed. 
Some of the seemingly disparate procedures de-
scribed may modify the graft in such a way that it 
is more likely to evoke blocking or enhancing 
antibodies than a cellular immune response, i.e., to 
evoke an altered host response. As Jacobs and 
Uphoff [10] have cogently argued in a recent 
review, to understand graft adaptation, host adap-
tation must be taken into consideration. Better 
understanding of the principles involved may lead 
to the more strikingly prolonged survival of 
"adapted" grafts and to the eventual clinical 
application of some of them to help reduce the 
immunosuppressive treatment needed by patients 
during the early postgrafting period. 
Because of their proliferative and associated 
ability to override some histocompatibility bar-
riers, malignant cells maintained in vivo or in vitro 
have afforded particularly favorable material with 
which to evaluate the extent to which immunolog-
ically or otherwise based selective processes can 
produce hypoimmunogenic clones of cells. In mice, 
malignant cell lines have been produced which are 
characterized by a reduced complement of H-2 
locus and other important specificities on the cell 
membranes [73]. It is important to emphasize that 
this process of antigenic simplification has never 
been completed. Trophoblast and its natural ma-
lignant derivative, choriocarcinoma, appear to rep-
resent the only (natural) exceptions to this state-
ment. 
All "simplified" tumors retain the essential 
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characteristics of allografts in the sense that hosts 
can always be specifically presensitized against 
them. In murine tumors, individual H-2 and other 
specificities are retained, probably because they 
are essential for viability. These observations are 
important in the present context since they indi-
cate that no graft adaptation procedure is at all 
likely to provide a complete solution to the clinical 
allograft problem. 
I am exceedingly grateful to my colleague, Dr. Alan E. 
Beer, for helpful criticism and advice. 
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